108.91
price down icon1.01%   -1.11
after-market 시간 외 거래: 108.13 -0.78 -0.72%
loading
전일 마감가:
$110.02
열려 있는:
$109.15
하루 거래량:
867.91K
Relative Volume:
0.81
시가총액:
$26.18B
수익:
$2.97B
순이익/손실:
$-812.83M
주가수익비율:
-32.07
EPS:
-3.3962
순현금흐름:
$-1.24B
1주 성능:
-1.88%
1개월 성능:
+2.23%
6개월 성능:
-7.11%
1년 성능:
+27.44%
1일 변동 폭
Value
$108.63
$110.93
1주일 범위
Value
$108.63
$112.58
52주 변동 폭
Value
$76.53
$131.49

바이오앤테크 Stock (BNTX) Company Profile

Name
명칭
Biontech Se Adr
Name
전화
-
Name
주소
-
Name
직원
6,772
Name
트위터
@BioNTech_Group
Name
다음 수익 날짜
2025-03-10
Name
최신 SEC 제출 서류
Name
BNTX's Discussions on Twitter

BNTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BNTX
Biontech Se Adr
108.91 26.68B 2.97B -812.83M -1.24B -3.3962
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

바이오앤테크 Stock (BNTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-05 재확인 H.C. Wainwright Buy
2025-05-29 개시 Goldman Neutral
2025-03-13 개시 Citigroup Buy
2025-01-10 개시 Truist Buy
2024-12-11 개시 Wells Fargo Overweight
2024-12-02 재확인 BMO Capital Markets Outperform
2024-11-19 개시 Berenberg Buy
2024-11-19 업그레이드 Evercore ISI In-line → Outperform
2024-11-08 업그레이드 Goldman Neutral → Buy
2024-09-24 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-09-17 업그레이드 Jefferies Hold → Buy
2024-09-16 업그레이드 JP Morgan Underweight → Neutral
2024-08-07 업그레이드 Deutsche Bank Hold → Buy
2024-08-02 업그레이드 HSBC Securities Hold → Buy
2024-05-14 개시 Evercore ISI In-line
2024-02-23 개시 BMO Capital Markets Outperform
2024-01-05 개시 Oppenheimer Perform
2023-12-01 다운그레이드 JP Morgan Neutral → Underweight
2023-10-16 다운그레이드 HSBC Securities Buy → Hold
2023-07-14 개시 HSBC Securities Buy
2023-05-17 업그레이드 Redburn Neutral → Buy
2022-12-15 업그레이드 BofA Securities Neutral → Buy
2022-08-17 개시 Cowen Market Perform
2022-07-13 업그레이드 SVB Leerink Mkt Perform → Outperform
2022-07-06 재개 Canaccord Genuity Buy
2022-02-01 업그레이드 Redburn Sell → Neutral
2021-12-16 개시 Morgan Stanley Equal-Weight
2021-11-10 업그레이드 H.C. Wainwright Neutral → Buy
2021-10-22 개시 Deutsche Bank Hold
2021-10-07 개시 Jefferies Hold
2021-08-11 업그레이드 Bryan Garnier Neutral → Buy
2021-07-19 재개 Wolfe Research Outperform
2021-06-16 다운그레이드 Redburn Neutral → Sell
2021-05-18 개시 Goldman Neutral
2021-05-11 다운그레이드 Bryan Garnier Buy → Neutral
2020-12-01 다운그레이드 BofA Securities Buy → Neutral
2020-08-03 재개 Berenberg Buy
2020-07-21 업그레이드 BofA Securities Neutral → Buy
2020-06-30 다운그레이드 H.C. Wainwright Buy → Neutral
2020-05-19 업그레이드 H.C. Wainwright Neutral → Buy
2020-04-28 다운그레이드 BofA/Merrill Buy → Neutral
2020-03-18 다운그레이드 JP Morgan Overweight → Neutral
2020-03-09 개시 H.C. Wainwright Neutral
2020-01-24 다운그레이드 SVB Leerink Outperform → Mkt Perform
2020-01-22 다운그레이드 UBS Buy → Neutral
2019-11-05 개시 Wolfe Research Outperform
2019-11-04 개시 Berenberg Buy
2019-11-04 개시 BofA/Merrill Buy
2019-11-04 개시 Canaccord Genuity Buy
2019-11-04 개시 JP Morgan Overweight
2019-11-04 개시 SVB Leerink Outperform
2019-11-04 개시 UBS Buy
모두보기

바이오앤테크 주식(BNTX)의 최신 뉴스

pulisher
Jul 20, 2025

BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN

Jul 20, 2025
pulisher
Jul 18, 2025

Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks

Jul 18, 2025
pulisher
Jul 17, 2025

BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva

Jul 17, 2025
pulisher
Jul 13, 2025

OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 13, 2025
pulisher
Jul 11, 2025

BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest

Jul 11, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jul 10, 2025
pulisher
Jul 10, 2025

GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 03, 2025

BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 03, 2025
pulisher
Jul 02, 2025

BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

BioNTech ADR Earns Relative Strength Rating Upgrade - MSN

Jul 01, 2025
pulisher
Jul 01, 2025

Biontech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 01, 2025
pulisher
Jun 30, 2025

BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily

Jun 27, 2025
pulisher
Jun 26, 2025

BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jun 26, 2025
pulisher
Jun 26, 2025

BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks

Jun 26, 2025
pulisher
Jun 24, 2025

BioNTech’s BNT327: A Promising Phase II Trial for Small-Cell Lung Cancer - TipRanks

Jun 24, 2025
pulisher
Jun 20, 2025

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research

Jun 20, 2025
pulisher
Jun 19, 2025

Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World

Jun 19, 2025
pulisher
Jun 19, 2025

BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX

Jun 17, 2025
pulisher
Jun 16, 2025

5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga

Jun 16, 2025
pulisher
Jun 12, 2025

Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

BMY Reports Positive Data On Sotyktu From Arthritis Study - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

CureVac stock soars about 30% after BioNTech agrees to acquire co By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 10, 2025

Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail

Jun 10, 2025
pulisher
Jun 10, 2025

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga

Jun 10, 2025
pulisher
Jun 06, 2025

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail

Jun 06, 2025
pulisher
Jun 03, 2025

Is BioNTech Stock A Buy On Major $11 Billion Cancer-Drug Deal? - Barchart.com

Jun 03, 2025
pulisher
Jun 03, 2025

Bristol Myers Collaborates With BNTX for Oncology Candidate - sharewise

Jun 03, 2025

바이오앤테크 (BNTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
biotechnology ONC
$291.93
price down icon 0.89%
$26.34
price up icon 0.53%
$102.78
price up icon 0.22%
$566.14
price up icon 0.27%
$35.65
price up icon 0.17%
자본화:     |  볼륨(24시간):